CAR-T Cell therapy could be made safer and more widely available with a few adjustments

A revolutionary approach to CAR-T cell therapy has the potential to challenge the longstanding assumption that the treatment's remarkable effect on tumours inevitably comes at the expense of substantial risks to patient safety. Researchers starting with Novartis' FDA-approved Kymriah created their own analogues, each assembled with a slightly different amino acid sequence, and discovered that one of the modified CAR-T variants was able to kill cancer cells without inducing a feverish immune response or generating brain inflammation — two of the most prevalent significant side effects of cell treatment. In a trial enrolling 25 individuals in China, the altered Kymriah caused no major cases of cytokine release syndrome and no neurotoxicity, a striking contrast to Novartis' published research in which more than half of patients experienced cytokine release and around a quarter had neurological issues. Dr. Si-Yi Chen, an immunology professor at the University of Southern California and the paper's primary author, described the result as "a really huge surprise," with the modified CAR-T appearing to have found an immunological sweet spot that attracts just enough cytokines to affect cancer without causing significant harm.

While the early results are promising, experts have urged caution, with Dr. Loretta Nastoupil of MD Anderson Cancer Center emphasizing that understanding the processes behind the modified therapy's efficacy will be crucial before broader conclusions can be drawn. Dr. Michel Sadelain of Memorial Sloan Kettering Cancer Center raised the key question of whether weakening the CAR to reduce cytokine production might also reduce its long-term therapeutic effect, noting that only time will tell whether the remissions achieved will prove as durable as those seen with approved CAR-T therapies. Beyond the science, a safer CAR-T could significantly expand access to a treatment currently limited to large cancer institutions, as the severe side effects of existing therapies require specialist care and expertise unavailable at community hospitals. The cost burden is also considerable, with CAR-T treatment priced upwards of $370,000 per infusion and total costs in the most severe cases frequently approaching $1 million when hospitalization and immune-suppressing medicines are included.